Myovant Sciences Stock Price, News & Analysis (NYSE:MYOV)

$15.11 +0.17 (+1.14 %)
(As of 02/21/2018 02:26 PM ET)
Previous Close$14.94
Today's Range$14.81 - $15.18
52-Week Range$9.92 - $18.85
Volume27,772 shs
Average Volume25,669 shs
Market Capitalization$905.69 million
P/E Ratio-7.62
Dividend YieldN/A
Beta-0.06

About Myovant Sciences (NYSE:MYOV)

Myovant Sciences logoMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Receive MYOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MYOV
CUSIPN/A
Phone203-318-9709

Debt

Debt-to-Equity Ratio0.35%
Current Ratio5.04%
Quick Ratio5.04%

Price-To-Earnings

Trailing P/E Ratio-7.62241008974444
Forward P/E Ratio-7.30
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.35 per share
Price / Book11.19

Profitability

Trailing EPS($1.96)
Net Income$-83,440,000.00
Net MarginsN/A
Return on Equity-90.86%
Return on Assets-74.94%

Miscellaneous

Employees36
Outstanding Shares60,990,000

Myovant Sciences (NYSE:MYOV) Frequently Asked Questions

What is Myovant Sciences' stock symbol?

Myovant Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "MYOV."

When will Myovant Sciences make its next earnings announcement?

Myovant Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, June, 13th 2018. View Earnings Estimates for Myovant Sciences.

Where is Myovant Sciences' stock going? Where will Myovant Sciences' stock price be in 2018?

4 Wall Street analysts have issued 1-year target prices for Myovant Sciences' shares. Their predictions range from $20.00 to $25.00. On average, they expect Myovant Sciences' share price to reach $22.50 in the next twelve months. View Analyst Ratings for Myovant Sciences.

What are Wall Street analysts saying about Myovant Sciences stock?

Here are some recent quotes from research analysts about Myovant Sciences stock:

  • 1. According to Zacks Investment Research, "Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. " (2/20/2018)
  • 2. Cowen Inc analysts commented, "Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of." (11/14/2017)

Who are some of Myovant Sciences' key competitors?

Who are Myovant Sciences' key executives?

Myovant Sciences' management team includes the folowing people:

  • Lynn Seely M.D., Principal Executive Officer, Director (Age 58)
  • Frank L. Karbe, Principal Financial, Accounting Officer (Age 49)
  • Marianne L. Romeo, Head, Global Transactions & Risk Management (Age 49)
  • Terrie Curran, Director (Age 48)
  • Keith S. Manchester M.D., Director (Age 48)
  • Vivek Ramaswamy, Director (Age 31)
  • Mark Altmeyer, Independent Director (Age 56)
  • Wayne S. DeVeydt, Independent Director (Age 47)

When did Myovant Sciences IPO?

(MYOV) raised $176 million in an initial public offering on Thursday, October 27th 2016. The company issued 13,000,000 shares at a price of $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who owns Myovant Sciences stock?

Myovant Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Emory University (0.22%), Ardsley Advisory Partners (0.16%) and Millennium Management LLC (0.11%). View Institutional Ownership Trends for Myovant Sciences.

Who sold Myovant Sciences stock? Who is selling Myovant Sciences stock?

Myovant Sciences' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Emory University. View Insider Buying and Selling for Myovant Sciences.

Who bought Myovant Sciences stock? Who is buying Myovant Sciences stock?

Myovant Sciences' stock was acquired by a variety of institutional investors in the last quarter, including Ardsley Advisory Partners. View Insider Buying and Selling for Myovant Sciences.

How do I buy Myovant Sciences stock?

Shares of Myovant Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Myovant Sciences' stock price today?

One share of Myovant Sciences stock can currently be purchased for approximately $15.11.

How big of a company is Myovant Sciences?

Myovant Sciences has a market capitalization of $905.69 million. The company earns $-83,440,000.00 in net income (profit) each year or ($1.96) on an earnings per share basis. Myovant Sciences employs 36 workers across the globe.

How can I contact Myovant Sciences?

Myovant Sciences' mailing address is 11-12 ST. JAMES SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 203-318-9709 or via email at [email protected]


MarketBeat Community Rating for Myovant Sciences (MYOV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  67 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about Myovant Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Myovant Sciences (NYSE:MYOV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.50$22.50$22.50$19.50
Price Target Upside: 67.54% upside67.54% upside67.54% upside96.37% upside

Myovant Sciences (NYSE:MYOV) Consensus Price Target History

Price Target History for Myovant Sciences (NYSE:MYOV)

Myovant Sciences (NYSE:MYOV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2017CowenReiterated RatingBuyN/AView Rating Details
11/10/2017Robert W. BairdReiterated RatingBuy$20.00N/AView Rating Details
10/4/2017JMP SecuritiesReiterated RatingOutperform$23.00 -> $25.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> OutperformHighView Rating Details
11/21/2016CitigroupInitiated CoverageBuy$17.00N/AView Rating Details
11/21/2016BarclaysInitiated CoverageOverweight$18.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Myovant Sciences (NYSE:MYOV) Earnings History and Estimates Chart

Earnings by Quarter for Myovant Sciences (NYSE:MYOV)

Myovant Sciences (NYSE MYOV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/13/2018        
11/13/2017Q2 2018($0.38)($0.50)ViewN/AView Earnings Details
8/10/2017Q1 2018($0.29)($0.39)ViewN/AView Earnings Details
6/14/2017Q4 2017($0.37)ViewN/AView Earnings Details
2/13/2017Q3 2017($0.33)($0.15)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Myovant Sciences (NYSE:MYOV) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.07 EPS
Next Year EPS Consensus Estimate: $-1.58 EPS

Dividends

Dividend History for Myovant Sciences (NYSE:MYOV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Myovant Sciences (NYSE MYOV)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Myovant Sciences (NYSE MYOV) News Headlines

Source:
DateHeadline
Head to Head Analysis: Myovant Sciences (MYOV) & Sonoma Pharmaceuticals (SNOA)Head to Head Analysis: Myovant Sciences (MYOV) & Sonoma Pharmaceuticals (SNOA)
www.americanbankingnews.com - February 21 at 1:30 AM
Zacks Investment Research Downgrades Myovant Sciences (MYOV) to SellZacks Investment Research Downgrades Myovant Sciences (MYOV) to Sell
www.americanbankingnews.com - February 20 at 6:58 AM
 Analysts Expect Myovant Sciences Ltd (MYOV) to Post -$0.46 EPS Analysts Expect Myovant Sciences Ltd (MYOV) to Post -$0.46 EPS
www.americanbankingnews.com - February 15 at 9:10 PM
Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017
finance.yahoo.com - February 13 at 4:28 PM
Contrasting Peregrine Pharmaceuticals (CDMO) & Myovant Sciences (MYOV)Contrasting Peregrine Pharmaceuticals (CDMO) & Myovant Sciences (MYOV)
www.americanbankingnews.com - February 5 at 1:39 PM
Myovant Sciences Ltd (MYOV) Expected to Announce Earnings of -$0.42 Per ShareMyovant Sciences Ltd (MYOV) Expected to Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - January 29 at 11:16 PM
Financial Survey: Anika Therapeutics (ANIK) and Myovant Sciences (MYOV)Financial Survey: Anika Therapeutics (ANIK) and Myovant Sciences (MYOV)
www.americanbankingnews.com - January 14 at 11:30 AM
Myovant Sciences to Present at the 36th Annual J.P. Morgan Healthcare ConferenceMyovant Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:10 AM
Myovant Sciences (MYOV) & Argos Therapeutics (ARGS) Financial ComparisonMyovant Sciences (MYOV) & Argos Therapeutics (ARGS) Financial Comparison
www.americanbankingnews.com - January 3 at 10:14 AM
Analyzing Myovant Sciences (MYOV) & Alexion Pharmaceuticals (ALXN)Analyzing Myovant Sciences (MYOV) & Alexion Pharmaceuticals (ALXN)
www.americanbankingnews.com - December 29 at 3:24 PM
Myovant Sciences (MYOV) & Ocera Therapeutics (OCRX) Financial AnalysisMyovant Sciences (MYOV) & Ocera Therapeutics (OCRX) Financial Analysis
www.americanbankingnews.com - December 28 at 9:29 AM
-$0.42 Earnings Per Share Expected for Myovant Sciences Ltd (MYOV) This Quarter-$0.42 Earnings Per Share Expected for Myovant Sciences Ltd (MYOV) This Quarter
www.americanbankingnews.com - December 27 at 10:50 AM
Head to Head Comparison: Myovant Sciences (MYOV) and Argos Therapeutics (ARGS)Head to Head Comparison: Myovant Sciences (MYOV) and Argos Therapeutics (ARGS)
www.americanbankingnews.com - December 19 at 3:16 AM
Financial Review: Onconova Therapeutics (ONTX) versus Myovant Sciences (MYOV)Financial Review: Onconova Therapeutics (ONTX) versus Myovant Sciences (MYOV)
www.americanbankingnews.com - December 17 at 11:32 AM
Myovant Sciences (MYOV) and Syndax Pharmaceuticals (SNDX) Financial ContrastMyovant Sciences (MYOV) and Syndax Pharmaceuticals (SNDX) Financial Contrast
www.americanbankingnews.com - December 14 at 5:40 PM
Myovant Sciences (MYOV) versus Its Peers Financial AnalysisMyovant Sciences (MYOV) versus Its Peers Financial Analysis
www.americanbankingnews.com - December 11 at 3:34 PM
Head-To-Head Contrast: Auxilium Pharmaceuticals (AUXL) vs. Myovant Sciences (MYOV)Head-To-Head Contrast: Auxilium Pharmaceuticals (AUXL) vs. Myovant Sciences (MYOV)
www.americanbankingnews.com - December 11 at 1:26 AM
Critical Comparison: Myovant Sciences (MYOV) vs. Its RivalsCritical Comparison: Myovant Sciences (MYOV) vs. Its Rivals
www.americanbankingnews.com - December 10 at 5:22 PM
Comparing Myovant Sciences (MYOV) & The CompetitionComparing Myovant Sciences (MYOV) & The Competition
www.americanbankingnews.com - December 10 at 5:20 PM
 Brokerages Expect Myovant Sciences Ltd (MYOV) to Announce -$0.42 Earnings Per Share Brokerages Expect Myovant Sciences Ltd (MYOV) to Announce -$0.42 Earnings Per Share
www.americanbankingnews.com - December 9 at 11:42 PM
Contrasting Cardiome Pharma (CRME) & Myovant Sciences (MYOV)Contrasting Cardiome Pharma (CRME) & Myovant Sciences (MYOV)
www.americanbankingnews.com - December 9 at 5:30 AM
Myovant Sciences (MYOV) and The Competition Head to Head AnalysisMyovant Sciences (MYOV) and The Competition Head to Head Analysis
www.americanbankingnews.com - December 8 at 1:30 AM
Comparing Myovant Sciences (MYOV) & Its RivalsComparing Myovant Sciences (MYOV) & Its Rivals
www.americanbankingnews.com - December 8 at 1:30 AM
Critical Contrast: Myovant Sciences (MYOV) and Its CompetitorsCritical Contrast: Myovant Sciences (MYOV) and Its Competitors
www.americanbankingnews.com - December 3 at 9:48 PM
Myovant Sciences (MYOV) versus The Competition Head to Head ComparisonMyovant Sciences (MYOV) versus The Competition Head to Head Comparison
www.americanbankingnews.com - November 30 at 3:12 AM
Myovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep Dive ConferenceMyovant Sciences to Participate in the Evercore ISI BioPharma Catalyst / Deep Dive Conference
finance.yahoo.com - November 22 at 6:02 AM
 Brokerages Anticipate Myovant Sciences Ltd. (MYOV) Will Post Earnings of -$0.42 Per Share Brokerages Anticipate Myovant Sciences Ltd. (MYOV) Will Post Earnings of -$0.42 Per Share
www.americanbankingnews.com - November 21 at 11:26 PM
Head to Head Survey: Myovant Sciences (MYOV) & Its CompetitorsHead to Head Survey: Myovant Sciences (MYOV) & Its Competitors
www.americanbankingnews.com - November 21 at 11:20 AM
Reviewing Myovant Sciences (MYOV) and Its RivalsReviewing Myovant Sciences (MYOV) and Its Rivals
www.americanbankingnews.com - November 21 at 5:12 AM
Myovant Sciences Ltd. (MYOV) Receives Consensus Recommendation of "Buy" from AnalystsMyovant Sciences Ltd. (MYOV) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 20 at 12:34 PM
Myovant Sciences Ltd. (MYOV) Downgraded by Zacks Investment Research to "Sell"Myovant Sciences Ltd. (MYOV) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - November 18 at 6:18 PM
Myovant Sciences (MYOV) & Its Peers Head-To-Head SurveyMyovant Sciences (MYOV) & Its Peers Head-To-Head Survey
www.americanbankingnews.com - November 16 at 7:10 PM
Head to Head Review: Myovant Sciences (MYOV) and Its CompetitorsHead to Head Review: Myovant Sciences (MYOV) and Its Competitors
www.americanbankingnews.com - November 15 at 3:30 PM

SEC Filings

Myovant Sciences (NYSE:MYOV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Myovant Sciences (NYSE:MYOV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Myovant Sciences (NYSE MYOV) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.